Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis

Published:2021-02-15 Issue:4 Volume:100 Page:1003-1012
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Hu Linhui,Charwudzi Alice,Li Qian,Zhu Weiwei,Tao Qianshan,Xiong Shudao,Zhai Zhimin^ORCID

Funder

National Natural Science Foundation of China

major subject of science and technology of Anhui province

Key Research and Development Plan of Anhui Province

Foundation of Anhui Medical University

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-021-04451-w.pdf

Reference47 articles.

1. Chen B, Wang YY, Shen Y, Zhang WN, He HY, Zhu YM, Chen HM, Gu CH, Fan X, Chen JM, Cao Q, Yang G, Jiang CL, Weng XQ, Zhang XX, Xiong SM, Shen ZX, Jiang H, Gu LJ, Chen Z, Mi JQ, Chen SJ (2012) Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries. Leukemia 26(7):1608–1616

2. Liu K, Chu J, Dai Y, Jiang A, Yang L, Xie Z et al (2020) (2020) Long-term follow-up of acute lymphoblastic leukemia in young children treated by the SCMC-ALL-2009 protocol. Leuk Lymphoma. 61(12):2850–2858

3. Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, O’Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB (2018) Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv 2(12):1449–1458

4. Moricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G et al (2016) Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 127(17):2101–2112

5. Takahashi H, Kajiwara R, Kato M, Hasegawa D, Tomizawa D, Noguchi Y, Koike K, Toyama D, Yabe H, Kajiwara M, Fujimura J, Sotomatsu M, Ota S, Maeda M, Goto H, Kato Y, Mori T, Inukai T, Shimada H, Fukushima K, Ogawa C, Makimoto A, Fukushima T, Ohki K, Koh K, Kiyokawa N, Manabe A, Ohara A (2018) Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. Int J Hematol 108(1):98–108

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia;Heliyon;2024-07

2. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review (protocol);Open Research Europe;2024-05-21

3. Predictive model for CAR‐T cell therapy success in patients with relapsed/refractory B‐cell acute lymphoblastic leukaemia;Scandinavian Journal of Immunology;2024-01-16

4. 4SCAR2.0 therapy for the management of post-transplantation relapse of B-cell acute lymphoblastic leukemia;Frontiers in Hematology;2023-11-09

5. Quartic CAR-T Cell Bridging to Twice Allo-HSCT Therapy in a Patient with Acute Lymphoblastic Leukemia;Transfusion Medicine and Hemotherapy;2023-08-22